7,500 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by Fayez Sarofim & Co

Fayez Sarofim & Co acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 7,500 shares of the biopharmaceutical company's stock, valued at approximately $359,000.

Several other institutional investors also recently bought and sold shares of HALO. Smartleaf Asset Management LLC boosted its stake in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 197 shares during the period. Louisiana State Employees Retirement System boosted its stake in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company's stock valued at $1,688,000 after purchasing an additional 200 shares during the period. CreativeOne Wealth LLC boosted its stake in shares of Halozyme Therapeutics by 1.6% in the fourth quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company's stock valued at $879,000 after purchasing an additional 294 shares during the period. State of New Jersey Common Pension Fund D boosted its stake in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company's stock valued at $2,279,000 after purchasing an additional 302 shares during the period. Finally, Parkside Financial Bank & Trust boosted its stake in shares of Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 322 shares during the period. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the sale, the senior vice president now directly owns 185,453 shares in the company, valued at approximately $10,765,546.65. The trade was a 5.12 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the sale, the director now directly owns 33,611 shares of the company's stock, valued at approximately $1,972,629.59. This represents a 12.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,200 shares of company stock valued at $1,286,568 in the last quarter. Company insiders own 2.40% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on HALO shares. Wells Fargo & Company cut their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. JPMorgan Chase & Co. upped their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Benchmark reaffirmed a "buy" rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. HC Wainwright reaffirmed a "buy" rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a report on Friday. Finally, Piper Sandler upped their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, Halozyme Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $62.89.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded up $1.24 on Friday, reaching $60.49. 992,970 shares of the company's stock were exchanged, compared to its average volume of 1,438,838. The firm has a market capitalization of $7.47 billion, a price-to-earnings ratio of 17.64, a PEG ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.97 and a fifty-two week high of $66.00. The business's 50-day moving average is $60.50 and its two-hundred day moving average is $55.14. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $298.01 million for the quarter, compared to analysts' expectations of $285.74 million. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.